[ Home ] [ Controlled Substances ] [ Stimulants ]
NEA
|
Etilamfetamine (Apetinil) is a stimulant drug of amphetamine chemical class. It is an N-substituted amphetamine with an ethyl group on the amphetamine backbone. It was used as an anorectic or appetite suppressant. Etilamfetamine is a psychoactive drug, which can be used as a recreational drug. Etilamfetamine has been abused as a "designer drug" alternative to amphetamine and possibly methamphetamine. It is a dopamine releasing agent.
Etilamfetamine (Apetinil):
https://drugs.ncats.io/drug/022YON1XMX
https://www.caymanchem.com/msdss/11557m.pdf
It was invented in the early 20th century and was subsequently used as an anorectic or appetite suppressant in the 1950s, but was not as commonly used as other amphetamines. was largely discontinued once newer drugs such as phenmetrazine were introduced. It most likely acts primarily as a dopamine releasing agent. Its activity as a norepinephrine or serotonin releasing agent is not known. Ethylamphetamine can be used as a recreational drug and, while its prevalence is less than amphetamine's, it is still encountered as a substance taken for recreational purposes. Ethylamphetamine produces effects similar to amphetamine and methamphetamine, though its potency is less. At equipotent dosage, ethylamphetamine is subjectively less euphorigenic.
State police to participate in NEA drug take-back - The Drug Enforcement Administration (DEA) is sponsoring the 27th nationwide “Prescription Drug Take Back” initiative on Saturday. The “Take Back” initiative seeks to prevent prescription drug abuse ... Wednesday October 23, 2024 - therepublic.com Cydan, a New Orphan Drug Accelerator, Launches with $16 Million Financing from Leading Investors NEA, Pfizer Venture Investments and Alexandria Real Estate Equities - CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- Cydan, LLC, an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential, today announced its launch with $16 million ... NEA leads $16M round for drug-eluting balloon firm - CV Ingenuity has inflated its coffers with a fresh round of venture cash amid development of its drug-eluting balloon technology. The Palo Alto, CA-based medical devices firm has raised $16 million in ... Mersana grabs $27M from Pfizer, NEA and others for muscled cancer drugs - Fresh from revealing a $2.6 billion fund last week, New Enterprise Associates (NEA) has jumped aboard as a lead backer of Mersana Therapeutics' next-gen antibody drug conjugates--one of the hottest ... NEA leads $16m investment in orphan drug accelerator - New Enterprise Associates is betting on an accelerator concept to solve the de-risking riddle inherent to orphan drugs — that is, those targeting rare diseases — and identifying promising orphan drug ... NEA Venture Partner Scott Gottlieb, M.D., Nominated To Be Commissioner Of U.S. Food And Drug Administration - CHEVY CHASE, Md., March 11, 2017 /PRNewswire/ -- New Enterprise Associates, Inc. (NEA) Venture Partner Scott Gottlieb, M.D., has been nominated by President Donald J. Trump to serve as Commissioner of ... NEA's Jim Barrett: Drug innovation should be rewarded - Society needs to “take seriously the rewards for innovators” through the patent system to improve the biotech investing climate, New Enterprise Associates Inc. General Partner James Barrett said ... Major drug bust nets 18 arrests in NEA - Federal and state law enforcement officials have arrested 18 individuals in Poinsett County following a large-scale drug investigation targeting methamphetamine distribution in Northeast Arkansas. The ... 15-year-old among 5 people caught for possessing e-vaporisers in HSA, NEA crackdown - Five people, aged between 15 and 37, were caught for possessing e-vaporisers and other related components during joint enforcement operations by the Health Sciences Authority (HSA) and the National ... NEA Backs Startup’s Software to Assess Drug Performance - Venture capitalists increasingly are backing startups that blend computer science and biology in a bid to accelerate drug discovery and the development of novel therapies. Aetion Inc., whose software ...
| ||
| Stimulants | Link to this page |